Communicators

are winners!

More News

24.07.2023
Scientia Clinical Research Subjects Dosed in RECCE® 327 Rapid Infusion Phase I/II UTI Clinical Trial
20.07.2023
Clarification – 5-fold Increase to Concentration of RECCE® 327 in Urine and Plasma
19.07.2023
Phase I Clinical Trial Data Review Complete - RECCE® 327 as an Intravenous Infusion Formulation
12.07.2023
Recce A$801,604 R&D Rebate Advance Received
10.07.2023
First Cohort Dosed in RECCE® 327 Rapid Infusion - Phase I/II UTI Clinical Trial
29.06.2023
Recce Pharmaceuticals Receives Ethics Approval for RECCE® 327 Faster Infusion, Phase I/II Clinical Trial Expansion
17.04.2023
Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Clinical Trial of RECCE® 327
11.04.2023
New Family 4 Patent to be Granted for RECCE® Anti-Infectives
04.04.2023
Recce Receives Further A$973,144 R&D Advance
20.02.2023
Recce Pharmaceuticals Selects CMAX Research Facility for Phase I/II Urinary Tract Infection Clinical Trial